(cHSV) and compared to shell vial culture (SV) as well as Prime Check HSV Antigen Detection Kit (PCA) and direct immunofluorescence (DFA). Diagnostic agreement was evaluated and discrepant analysis was performed by Sanger sequencing. Results The overall percent agreement (OPA), sensitivity and specificity of cHSV compared to SV for HSV-1 was 98.8% (95% CI 95.7-99.9), 100% (95% CI 97.8%-100%), and 98.5% (95% CI 95.3-99.8), and for HSV-2 was 87.9% (95% CI 81.9-92.5), 98.6% (95% CI 95.4%-99.8%), and 79.6% (95% CI 72.6%-85.4%), respectively. For HSV-1 there were 2 cHSV+/SV-. For HSV-2 there were 20 discordant results, 19 cHSV+/SV-and 1 cHSV-/SV+. Sanger Sequencing for HSV-1 confirmed 1 of 2 positive for HSV-1 and for HSV-2 confirmed 20/20 as HSV-2 positive. Both PCA and DFA missed more than twice as many confirmed positive HSV specimens as SV. The OPA, sensitivity and specificity of cHSV compared to DFA for HSV-1 was 84.8% (95% CI 78. Introduction Cheap and efficient pathogen detection solutions are required to replace syndromic STI management in low and middle income countries. One solution may be point-ofcare technologies at clinic level, another could be centralised high-throughput technologies. ThermoFisher recently launched the TaqMan Vaginal Microbiota Assays, in combination with OpenArray Nanofluidics qPCR platform, which is capable of testing 192 samples for 34 individual STI and bacterial vaginosis (BV) pathogens in a 2 hour qPCR run. The goal of this study was to evaluate OpenArray against an established multiplex PCR assay, and further optimise its workflow. Methods Evaluation of the TaqMan Vaginal Microbiota assays on OpenArray platform was performed for 50 vaginal micobiota vaginal swab samples that had been characterised for N. gonorrheae (NG), C. trachomatis (CT), and T. vaginalis (TV) on an established CDC-approved multiplex PCR assay. Blind samples were provided for testing on the OpenArray platform. Nugent scores were obtained in parallel to molecular testing and results were compared for 11 specific bacterial strains indicative of BV. Results High specificity (97.4%-100%) was observed at initial testing of STI samples, however the sensitivity was not as expected (NG 81.8%, CT 38.5%, TV 50.0%) due to concentrations of STI pathogens below the limit of detection on OpenArray, which was confirmed by 384-well plate testing (C RT range 33-38). Pre-amplification of STI samples improved the sensitivity significantly (NG 100%, CT 92%, TV 82%). Nugent scores for 46/50 samples were compared with the qPCR results for the BV-associated targets on OpenArray. BVassociated pathogens like G. vaginalis, A. vaginae, BVAB2, Megasphaera 1, Megasphara 2, M.hominis, and M. mulieris were predominate in the samples with Nugent Scores 7-10, while commensal lactobacillus were predominate in Nugent Scores 0-3. Conclusions After optimisation, the OpenArray Nanofluidics qPCR platform may provide a high-throughput solution for STI pathogen detection and for characterising the vaginal microbiota.
